The Ensign Group, Inc.
HealthcareNASDAQ:ENSG · NASDAQ Global Select
+$2.24 today
Vol 1.21M · Avg 0.54M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
15.4%
avg 15.3%
ROIC
6.9%
avg 6.9%
ROA
6.3%
avg 6.0%
Analysis
ROE is currently the strongest return metric at 15.4% versus its period average of 15.3%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Barry R. Port | Chief Executive Officer & Chairman of the Board | $10.89M | — | 52 | $21,352.00 | 0.04% |
Suzanne D. Snapper | Chief Financial Officer, Executive Vice President & Director | $9.38M | — | 52 | $292,467.00 | 0.50% |
Spencer W. Burton | President & Chief Operating Officer | $7.59M | — | 47 | $68,470.00 | 0.12% |
Chad A. Keetch | Chief Investment Officer, Executive Vice President & Secretary | $6.63M | — | 48 | $109,735.00 | 0.19% |
Beverly Wittekind | Executive Vice President & General Counsel | $1.19M | — | 61 | $33,135.00 | 0.06% |
Kevin Reese | President of Keystone Healthcare Inc | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
55
$16.48M
Net Sentiment
$16.48M
Net selling
Most Active
Snapper Suzanne D.
14 transactions
1–10 of 55
Analysis
Insiders reported 0 buys worth $0.00 and 55 sells worth $16.48M over the last 12 months. That adds up to net selling of $16.48M. Snapper Suzanne D. was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +4.5% | +18.0% (13yr)3 analysts |
| Revenue | N/A | N/A | +17.7% | +13.6% (13yr)3 analysts |
| Net Income | N/A | N/A | +10.9% | +18.9% (13yr)3 analysts |
| EBIT | N/A | N/A | +5.9% | +16.1% (13yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.7% over three years. Forward estimates point to Net Income at +18.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Solventum Corporation
NYSE:SOLV
$13.66B
DaVita Inc.
NYSE:DVA
$13.40B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.07B
Revvity, Inc.
NYSE:RVTY
$11.12B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Encompass Health Corporation
NYSE:EHC
$10.07B
Universal Health Services, Inc.
NYSE:UHS
$9.17B
Qiagen N.V.
NYSE:QGEN
$7.64B
Who manages ENSG?
The Ensign Group, Inc. (ENSG) lists 6 active executives. The top listed executive is Barry R. Port, Chief Executive Officer & Chairman of the Board.
Are ENSG insiders buying or selling?
Recent insider activity shows net buying of $10.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.